Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.

Thiery-Vuillemin A., Saad F., Armstrong A. J., Oya M., Vianna K. C. M., Ozguroglu M., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.16, 2022 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Özet
  • Cilt numarası: 40 Sayı: 16
  • Basım Tarihi: 2022
  • Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • İstanbul Üniversitesi Adresli: Evet